There are many factors that impact the success of a new therapy. Efficacy, differentiation, market size, and of course, cost. For this last point, the importance of factoring in payer perspectives and reimbursement dynamics within an indication should not be underestimated. Except many companies still do, even as they plough millions of dollars into pipeline products that must be paid for by someone if they are to be successful.
In this white paper, we look at what manufacturers of successful asset launches have done differently, and discuss how to positively impact the likelihood of a successful drug launch.
